key: cord-0987327-myw90bzv authors: Vitiello, Antonio; Ferrara, Francesco; Auti, Amogh M.; Di Domenico, Marina; Boccellino, Mariarosaria title: Advances in the Omicron variant development date: 2022-03-22 journal: J Intern Med DOI: 10.1111/joim.13478 sha: a2080126193c7a60fb4f9ed2c3b6ac369487813e doc_id: 987327 cord_uid: myw90bzv Severe acute respiratory syndrome coronavirus (SARS‐CoV)‐2 has spread worldwide, leading the World Health Organization (WHO) to declare a pandemic, on 11 March 2020. Variants of concern have appeared at regular intervals—Alpha, Beta, Gamma, Delta, and now Omicron. Omicron variant, first identified in Botswana in November 2021, is rapidly becoming the dominant circulating variant. In this review, we provide an overview regarding the molecular profile of the Omicron variant, epidemiology, transmissibility, the impact on vaccines, as well as vaccine escape, and finally, we report the pharmacological agents able to block the endocellular entry of SARS‐CoV‐2 or to inhibit its viral replication. The Omicron has more than 50 mutations, of which the spike protein has 26–35 amino acids different from the original SARS‐CoV‐2 virus or the Delta, some of which are associated with humoral immune escape potential and greater transmissibility. Omicron has a significant growth advantage over Delta, leading to rapid spread with higher incidence levels. The disease so far has been mild compared to the Delta. The two vaccination doses offer little or no protection against Omicron infection while the booster doses provide significant protection against mild illness and likely offer even greater levels of protection against serious illness. Recently, new oral antiviral agents such as molnupiravir and paxlovid have been approved and represent important therapeutic alternatives to antiviral remdesivir. In addition, monoclonal antibodies such as casirivimab/imdevimab bind different epitopes of the spike protein receptor; is this class of drugs effective against the Omicron variant? However, more research is needed to define whether Omicron is indeed more infectious and whether the vaccines, monoclonal antibodies, and antivirals currently available are effective. On 11 March 2020, the World Health Organization (WHO) classified coronavirus disease 2019 (COVID-19) as a global pandemic [1] . As of 18 December 2020, more than 1,600,000 deaths globally had been attributed to COVID-19 [2] . The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has been unprecedentedly fast, diffusing to more than 180 countries within 3 months with different severities. The COVID-19 pandemic is responsible for great mortality and severe morbidity in both developed and developing nations. Development of sensitive, specific, and rapid COVID-19 diagnostic tests aided to trace and control the infection [3, 4] . SARS-CoV-2 has the natural ability to undergo mutation and antigenic variation over a period of time. The SARS-CoV-2 virus was isolated and sequenced. The genome size varies from 29.8 kb to 29.9 kb and consists of four structural proteins: spike protein (S), envelope (E), membrane (M), and nucleocapsid (N) proteins [5] . S-glycoprotein is the central transmembrane monomer of approximately 180 kDa with two subunits, S1 and S2. It mediates membrane fusion and ultimately facilitates virus entry. The receptor binding domain (RBD) (residues 319-541) of the S1 subunit interacts with the angiotensin-converting enzyme 2 (ACE2), binding tightly to its peptidase domain [6] . The E protein, which is the smallest protein in the virus structure, plays a role in the maturation of this virus. The M protein is critical in determining the shape of the virus envelope and in stabilizing the nucleocapsids. The N protein is involved in processes related to the cellular response of host cells to viral infections, the viral replication cycle, and the viral genome. SARS-CoV-2 uses the ACE2 receptor for cellular entry in synergy with TMPRSS2, an important host factor that cleaves protein S, facilitating viral activation [7] . In the last 2 years, there have been a significant number of mutations that have led to the evolution of the virus and therefore to different variants [8] . WHO has classified them into three categories: variants of interest (VOIs), variants under monitoring (VUMs), and variants of concern (VOCs). For VOIs, there is still preliminary and uncertain evidence on genomic, epidemiological properties regarding a significant impact on transmissibility, severity, and/or immunity. The VUMs categories have been detected as signals through rule-based genomic variant screening or preliminary scientific evidence. Some indications seem to assign them similar properties to those of a VOC, but the evidence is weak or has not yet been assessed by European Centre for Disease Prevention and Control (ECDC). For VOCs, clear evidence indicated a significant impact on transmissibility, severity, or virus virulence with consequences on the epidemiological situation by reducing the effectiveness of public health measures, diagnostics, vaccines, and therapies [9, 10] . So far, we have five VOCs: Alpha (B.1.1.7, U.K. variant), Beta (B.1.351, South Africa), Gamma (P.1, Brazil), Delta (B.1.617.2, India), and Omicron (B.1.1.529, Africa). The Alpha, Beta, and Gamma variants have the same mutation, N501Y, on RBD, which increases affinity for ACE2 by increasing its transmissibility; in addition, the Beta and Gamma variants also show K417N and E484K mutations, which by decreasing the binding of neutralizing antibodies lead to a partial immune escape favoring reinfections [11] . All these factors contributed to a new wave of pandemic and thousands of deaths around the world [9] . The highly contagious Delta variant quickly spread around the world and replaced Alpha as the more prevalent variant. The Omicron variant, first identified in Botswana in November 2021, is rapidly becoming the dominant circulating variant. ), and 15 in the RBD, some of which may be associated with humoral immune escape potential and higher transmissibility [13] (Fig. 1) [13] . Several mutations in the RBD of the Omicron variant are shared by other SARS-CoV-2 variants. These are K417N, E484K, N501Y, D614G, and T478K. The K417N mutation with asparagine substitution to lysine is shared by both Omicron and Beta variants; in E484K variant at residue 484, glutamic acid is replaced by lysine in both Beta and Gamma variants; the mutation at 484 residues in Omicron is E484A, where glutamic acid is mutated to alanine. This mutation, also shared by Beta and Gamma variants, can cause reinfection, while the Omicron variant might alter the interaction between RBD and human ACE2. N501Y mutation (asparagine to tyrosine), already detected in the Alpha, Beta, and Gamma variants, determines a higher binding affinity to human ACE2. The D614G mutation with substitution of aspartic acid to glycine in S1 subunit of the Omicron variant is also present in Alpha, Beta, Gamma, and Delta variants. The T478K mutation with the replacement of threonine to lysine is shared by Delta variants (Table 1 ) [14] . In addition, the Omicron variant SARS-CoV-2 shares the deletion of amino acids H69 and V70 in the S-gene of its genome, which can cause an S gene target failure (SGTF) and for this reason, the PCR (polymerase chain reaction) tests most used to diagnose infection with SARS-CoV-2 do not detect the S gene on which these deletions are present. Although a small percentage of publicly shared sequences lack this deletion, SGTF can be used as a proxy marker for Omicron screening. In tests designed to detect multiple genetic targets, tests are expected to still detect the Omicron variant SARS-CoV-2, although one genetic target has reduced sensitivity due to mutation [15] . Therefore, the detection pattern, which shows dropout of the affected target, can be the indicative signal of the , deletion mutation; ins, insertion mutation; # mutation showed fusogenicity and pathogenicity. [19] . The greater prevalence of Omicron compared to Delta has now been confirmed by several pieces of evidence such as neutralization studies, the first estimates of the efficacy of vaccination against symptomatic disease, and studies on reinfection risk, which suggest that this is due to immune evasion against the infection. However, more data are needed to estimate the generation time of Omicron compared to the other variants and to understand whether Omicron has characteristics that make it more transmissible. Vaccines are the best and most reliable way to avoid and manage infectious diseases. The COVID-19 pandemic and the resulting increase in deaths worldwide have made the development of an effective SARS-CoV-2 vaccine urgently important. Immune evasion plays a significant role in the rapid growth in Omicron cases. The Omicron variant may be able to evade immunity from previous vaccines or infections more extensively than any other variant, making existing vaccines less effective against the variant [25] . In England, the risk of reinfection with Omicron was estimated to be 5.4 (95% CI: 4.87-6.00) times higher than with the Delta variant. The relative risks observed for unvaccinated and vaccinated cases were 6.36 (95% CI: 5.23-7.74) and 5.02 (95% CI: 4.47-5.67), respectively. Thus, the protection against reinfection can be as high as 19% [26] . The UK Health Security Agency determined that 5.9% of cases detected between 1 November and 13 December resulted from reinfection, evaluating the risk of reinfection with Omicron compared to other variants to be 3.3 (95% CI: 2.8-3.8) [27] . Pulliam et al. conducted a study analyzing routine surveillance data from South Africa, from which it emerged that the recent spread of the Omicron variant was associated with a decrease in the hazard coefficient for primary infection and an increase in the reinfection hazard coefficient [28] . A recent study with an Omicron spike pseudovirus showed that the Omicron variant significantly escaped from the neutralization of convalescent sera from early strain-or Delta-infected individuals; it also still requires ACE2 as its receptor and shows significantly increased infectivity. Neutralizing antibody titer in convalescent sera from Deltainfected patients decreased 39-fold, while that in convalescent sera from early-infected patients for Omicron decreased 36-fold, significantly less than neutralizing antibody titers for other variants. This indicates a significant immune escape from existing protection created by virus infection or vaccination [29] . The analysis of the binding of the Omicron RBD to human ACE2 and the capacity of human sera from infected or vaccinated patients with respect to the RBDs of the variants Beta or Delta or the original strain highlighted a reduction in binding antibodies' levels against the Omicron RBD. Serum titers against Beta and Delta RBDs were reduced, albeit to a lesser extent [30] . A further study showed that in convalescent and double vaccinated subjects, the neutralizing activity of sera against the Omicron variant was not detectable, while that of sera exposed to spikes three or four times, albeit at reduced levels, was maintained. In addition, binding to the Omicron RBD and NTD was reduced in convalescent not vaccinated but was mostly retained in vaccinated subjects. These studies add to the evidence that current vaccination protocols may be less effective against the Omicron variant [31] . Currently available data indicate that the Omicron variant is highly transmissible and that it spreads much faster than the other variants. The Omicron variant is estimated to infect 3-6 times as many people as the Delta variant and also infects individuals immune to the other variants. As of 12 December, 77 countries with Omicron presence have been reported [25, 32] . In South Africa, Omicron cases spread rapidly in Gauteng province in November, particularly in schools and among young people. [34] . The first case of Omicron in China was a person who arrived in Tianjin from a European country on 9 December 2021 and the second case was an individual who arrived from abroad identified in Guangzhou on 27 November 2021 [41] . Although data are still limited, few studies prove that symptoms are less severe and the risk of hospitalizations is lower than with the Delta variant. In South Africa, hospitalizations have been declining since the start of the Omicron wave, with tendencies towards hospitalization during the fourth phase mainly in the province of Gauteng. Indeed, according to a study on serological surveys in this province, Omicron infection rates have increased rapidly compared to the Delta variant but hospitalizations and deaths rested relatively low [42, 43] . December 2021 indicates a reduced risk of hospitalization for Omicron infection compared to the Delta variant. Omicron variant infection has been shown to have a 15%-20% reduced risk of hospitalization and a 41% reduced risk (95% CI: 37%-45%) of hospitalization with a stay of 1 or more nights [46] . The same trend was also observed in Scotland; in fact, the data on hospital admissions from 1 November to 19 December indicate a reduction of about two thirds of hospitalization risk for the Omicron variant compared to the Delta variant [20] . Furthermore, in Denmark, data collected up to 21 December indicate a lower percentage (0.6%) of hospitalizations for Omicron than that (1.6%) of other variants [47] . A Hong Kong study found that the Omicron variant replicates up to 70 times faster in human bronchi than Delta while replicating much slower in the lungs. This may be the reason for the less severe clinical presentation in patients with the Omicron variant [48] . Since the beginning of the COVID-19 pandemic, intense research activity has been carried out to identify, in the shortest time possible, pharmacological agents able to block the endocellular entry of SARS-CoV-2 or to inhibit its viral replication. An important contribution in this direction is represented by monoclonal antibodies against SARS-CoV-2 [49] . Monoclonal antibodies such as the combination casirivimab/imdevimab bind different epitopes of the spike protein receptor domain blocking interaction with ACE2 and causing inhibition of endocellular penetration of the virus [50] . The Omicron variant has at least 33 mutations in the S protein, and in particular 15 substitutions are in the RBD of the S protein, which is the primary molecular target of monoclonal antibodies. This may suggest that authorized monoclonal antibodies may be less effective against the Omicron variant. Recent in vitro studies have examined the neutralizing power of monoclonal antibodies against the Omicron variant [51] . Specifically, it was shown that almost all monoclonal antibodies have neutralizing efficacy against Alpha and Delta variants, and only bamlanivimab showed loss of efficacy against the Delta variant ( Table 2 ). In addition, loss of neutralizing efficacy against the Omicron variant was shown for the monoclonal antibodies bamlanivimab, etesevimab, and imdevimab [52, 53] . However, clinical evidence is urgently needed to test the efficacy of monoclonal antibodies against the Omicron variant. The other group of drugs that have revolutionized therapy against SARS-CoV-2 infection are directoral antivirals such as molnupiravir and paxlovid. Recently, new oral antiviral agents such as molnupiravir and paxlovid have been approved and represent important therapeutic alternatives to remdesivir. Molnupiravir is a prodrug that is immediately metabolized in its active form by plasma esterases. The active form of the drug then undergoes intracellular phosphorylation by host cell kinases to form an alternative substrate for viral RNA polymerase [54] . In vitro and in vivo tests show that molnupiravir was found to be a potent inhibitor of SARS-CoV-2 replication. The new oral antiviral agent paxlovid is a combination of two active drugs-nirmatrelvir (PF-07321332) acts by inhibiting SARS-CoV-2 viral replication by blocking the SARS-CoV-2-3CL protease, and ritonavir, an antiretroviral indicated for the treatment of HIV, which is also an inhibitor of cytochrome P4503A and CYP2D6, was used to slow the metabolism of nirmatrelvir. In vitro studies confirm that nirmatrelvir is a potent 3CL protease inhibitor of the Omicron variant, suggesting that the drug demonstrates potential therapeutic efficacy against this novel variant as well [55] . The Omicron variant has mutations in both the RNA-dependent RNA polymerase (RdRp) and the SARS-CoV-2 major protease, which are targets of antiviral drugs such as RdRp inhibitors (remdesivir and molnupiravir) and the major protease inhibitor nirmatrelvir. Current scientific evidence that analyzed in vitro 50% inhibitory concentration values (IC50) indicates that the susceptibility of Omicron to the three antiviral drugs is similar to that of previous variants [51] . A schematic overview of the efficacy of monoclonal antibodies and oral antivirals against SARS-CoV-2 variants is provided in Table 2 . Data were collected from evidence in PubMed. Early evidence suggests that all antivirals directed against SARS-CoV-2 may show clinical efficacy for the treatment of patients infected with the Omicron variant. However, further clinical studies are needed to fully demonstrate the efficacy of these antivirals against the Omicron variant. Several aspects of the Omicron variant are yet to be fully defined, such as whether or not it is more infectious than previous SARS-CoV-2 variants; whether it can cause a higher incidence of severe COVID-19 forms than other VOCs; and whether vaccines, monoclonal antibodies, and direct antivirals are effective. To date, the available immunological and clinical data cannot provide definitive evidence. However, from genomic analysis, the deletions and mutations present in the Omicron variant are known to lead to increased transmissibility due to higher viral binding affinity. Although early epidemiological data indicate rapid transmissibility and high contagiousness, to date no particularly alarming clinical concerns have been raised about an increased incidence of severe COVID-19 cases. In addition, the potential impact of Omicron on the clinical efficacy of COVID-19 infection vaccines is yet to be fully understood, even if the first epidemiological studies are very positive. Finally, early evidence indicates that for some monoclonal antibodies, there is a possible reduction in neutralizing power against the Omicron variant, while the new direct antivirals maintain their efficacy in inhibiting viral replication. Further clinical studies are needed to fully define these aspects. However, it is important to highlight that the preventive measures adopted with previous variants to protect public health, such as mask use, social distance, hand hygiene, and so on, and which have proven to be highly effective, still need to be adopted with the Omicron variant. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 New cases of COVID-19 in world countries Detection of SARS-COV-2 proteins using an ELISA test Diagnostic accuracy of a new antigen test for SARS-CoV-2 detection Genomic characterization of a novel SARS-CoV-2 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Race to find COVID-19 treatments accelerates The spike of concern-the novel variants of SARS-CoV-2 World Health Organization. Tracking SARS-CoV-2 variants Revised World Health Organization (WHO) terminology for variants of concern and variants of interest of SARS-CoV-2 SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance Omicron (B.1.1.529)-variant of concern-molecular profile and epidemiology: a mini review Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States World Health Organization WHO coronavirus (COVID-19) dashboard. 2022 Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update Centers for Disease Control and Prevention. COVID data tracker: monitoring variant proportions Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift A study to evaluate the immunogenicity and safety of mRNA-1273.211 vaccine for COVID-19 variants Omicron likely to weaken COVID vaccine protection Report: growth, population distribution and immune escape of Omicron in England SARS-CoV-2 variants of concern and variants under investigation in Englandtechnical briefing 32 Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate How bad is Omicron? Daily briefing: Omicron was already spreading in Europe UK raises COVID-19 alert level amid rising Omicron cases Omicron now accounts for 3% of US coronavirus cases Omicron variant detected in California's wastewater before WHO raises alarms: US media Omicron variant detected in California's wastewater before WHO raises alarms: US media Omicron potential under close scrutiny Daily briefing: Omicron coronavirus variant puts scientists on alert Experts: Omicron likely no worse than other variants No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway COVID-19 hospital surveillance update: South Africa-week 50 South African population immunity and severe Covid-19 with Omicron variant Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California Omicron daily overview: 22 Hospitalisation risk for Omicron cases in England Status of the SARS-CoV-2 variant Omicron in Denmark HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant Tackling COVID-19 with neutralizing monoclonal antibodies Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase Pfizer Featured Article. 2022 None. The authors declare no competing or financial interests.